

1 **Direct therapeutic effect of sulfadoxine-pyrimethamine on nutritional**
2 **deficiency-induced enteric dysfunction in a human intestine chip**

3
4 Seongmin Kim¹, Arash Naziripour¹, Pranav Prabhala¹, Viktor Horváth¹, Abidemi Junaid¹, David T.
5 Breault^{2,3,4}, Girija Goyal¹, Donald E. Ingber^{1,5,6*}

6
7 ¹Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115
8 ²Department of Pediatrics, Harvard Medical School, Boston, MA 02115
9 ³Department of Endocrinology, Boston Children's Hospital, Boston, MA 02115
10 ⁴Harvard Stem Cell Institute, Cambridge, MA 02138
11 ⁵Vascular Biology Program, Boston Children's Hospital and Department of Pathology, Harvard
12 Medical School, Boston, MA 02115
13 ⁶Harvard John A. Paulson School of Engineering and Applied Sciences, Cambridge, MA 02139

14
15 *Address all correspondence to: don.ingber@wyss.harvard.edu

16
17
18
19
20
21
22
23
24

25 **ABSTRACT**

26 Sulfadoxine-pyrimethamine (SP) antimalarial therapy has been suggested to improve the birth
27 weight of infants in pregnant women in sub-Saharan Africa independently of malarial infection.
28 Here, we investigated whether SP could have a direct impact on improving intestinal function,
29 thereby enhancing the absorption of essential fats and nutrients crucial for fetal growth.

30 Using a human organ-on-a-chip model, we replicated the adult female intestine with patient
31 organoid-derived duodenal epithelial cells interfaced with human intestinal endothelial cells.
32 Nutrient-deficient (ND) medium was perfused to simulate malnutrition, resulting in the appearance
33 of enteric dysfunction indicators such as villus blunting, reduced mucus production, impaired
34 nutrient absorption, and increased inflammatory cytokine secretion. SP was administered to these
35 chips in the presence or absence of human peripheral blood mononuclear cells (PBMCs).

36 Treatment with SP successfully reversed many abnormalities observed in malnourished chips,
37 as confirmed by transcriptomic and proteomic analysis. Notably, SP significantly enhanced
38 intestinal absorptive functions. Furthermore, SP suppressed the recruitment of PBMCs in the
39 nutrient deficient chips. SP may improve the birth weight of children born to malnourished mothers
40 by countering the effects of enteric dysfunction and suppressing inflammation. These findings
41 highlight the possibility of using SP as a direct intervention to improve maternal absorption and
42 subsequently contribute to healthier fetal growth.

43

44 **INTRODUCTION**

45 Malnutrition during pregnancy, particularly a lack of vital nutrients like iron, fat, calcium,
46 and zinc, can lead to adverse birth outcomes such as low birth weight and developmental delays
47 in children.^{1,2} Low birth weight is also an important indicator of infant mortality, which can be
48 caused by preterm birth, small size for gestational age, and malaria.² To combat malaria infection

49 and reduce the risk of adverse birth outcomes, the World Health Organization (WHO)
50 recommends intermittent preventive treatment with combined sulfadoxine and pyrimethamine (SP)
51 during pregnancy.³ Interestingly, a recent study found that maternal SP treatment can reduce the
52 incidence of low birth weight infants even in the absence of malarial infection and when the
53 organism is resistant to SP treatment.⁴ The physiological relevance of this observation remains
54 unclear as there is limited understanding of the effects of SP treatment on maternal health and
55 birth outcomes.

56 In this study, we aimed to investigate the effects of SP treatment on nutrient absorption in
57 the adult female small intestine and its impact on intestinal function using functional,
58 transcriptomic, and metabolic assays. To achieve this, we employed a microfluidic human organ-
59 on-a-chip model of the Intestine (Intestine Chip) that is lined by human intestinal epithelium
60 derived from organoids isolated from the duodenum of young adult females interfaced with
61 primary human intestinal microvascular endothelium. This model allowed us to directly assess the
62 potential therapeutic effects of SP on the intestine. To simulate malnutrition in the adult female
63 intestine, we exposed the Intestine Chip to nutritionally deficient (ND) medium lacking niacinamide
64 and tryptophan. We have previously demonstrated that human Intestine Chips cultured under
65 these ND conditions exhibited characteristic signs of environmental enteric dysfunction (EED),
66 such as villus blunting, decreased mucus production, and reduced absorption of fatty acids and
67 peptides, as well as altered transcriptomic profiles, consistent with previous clinical findings in
68 EED patients.⁵ Given the finding that SP seems to increase birth weight in maternal patients who
69 are resistant to the anti-malarial effects of this drug,⁴ we administered SP through the apical
70 epithelium-lined channel of the Intestine Chip to mimic oral administration in patients and
71 observed its effects under both healthy and ND conditions. Recognizing the complex interplay
72 between intestinal epithelial cells and the mucosal immune system,^{6,7} we also conducted
73 experiments using human peripheral blood mononuclear cells (PBMCs) introduced into the basal

74 endothelium-lined channel of the Intestine Chips. Our results demonstrate that SP has direct
75 protective effects on the malnourished adult female intestine.

76

77 **RESULTS**

78 ***SP mitigates the effects of nutritional deficiency in the human Intestine Chip***

79 In this study, we set out to address the adverse effects of nutritional deficiency (ND) using
80 an Intestine Chip model that faithfully replicates the structure and functionality of the human
81 intestine (figure 1A).⁹ Primary duodenal epithelial cells isolated from patient-derived organoids
82 were cultured on the upper extracellular matrix-coated surface of the porous membrane that
83 separates two parallel microchannels within the chips and primary human intestinal microvascular
84 endothelium was grown on the lower surface of the same membrane. The culture medium was
85 continuously perfused through both channels while peristalsis-like deformations were produced
86 by the application of cyclic suction to side chambers within the flexible polymer chip. Recreation
87 of the intestinal microenvironment in this manner leads to the spontaneous formation of intestinal
88 villi-like structures (figure 1B,C, and supplementary figure 1A). The chip also maintained an intact
89 intestinal barrier (figure 1D) and actively produced mucus (figure 1E,F), including Mucin 5B
90 (MUC5B) (figure 1G and supplementary figure 1B).

91 To simulate malnutrition conditions, we perfused the chips with ND medium which lacked
92 the essential nutrients niacinamide and tryptophan. This resulted in villus blunting (figure 1B,C,
93 and supplementary figure 1A), compromised barrier function (figure 1D), and reduced mucus
94 production (figure 1E,F, and supplementary figure 1B), as previously described.⁵ Consistent with
95 reduced barrier function, histological and immunofluorescence microscopic analysis revealed that
96 exposure to ND resulted in epithelial and cytoskeletal damage (supplementary figure 1A), as well
97 as partial disruption of VE cadherin-containing endothelial cell-cell contacts (supplementary figure
98 1C).

99 Considering the WHO recommendation of a high single dose (500 mg S + 25 mg P) of the
100 SP drug combination during pregnancy, we perfused the epithelial channel of the Intestine Chip
101 with the calculated acute duodenal dose ([133 μ g S + 6.7 μ g P]/mL) of this formulation as well as
102 lower doses (1/50th [2.66 μ g S + 0.13 μ g P]/mL and 1/10th [13.3 S + 0.67 μ g P]/mL) in culture
103 medium and assessed its effects on morphology, barrier function, and cytokine production. We
104 did not observe any significant changes in barrier permeability, epithelial morphology, or
105 inflammatory cytokine production in control Intestine Chips cultured with any of the SP doses
106 when tested in culture medium for three days (supplementary figure 2A-C). In contrast, SP
107 treatment resulted in a significant reversal of the ND phenotype in the malnourished Intestine
108 Chip. This was evidenced by increased villus height (figure 1B,C, and supplementary figure 1A),
109 improved barrier function (figure 1D), enhanced mucus production (figure 1E,F), and higher levels
110 of MUC5B (figure 1G and supplementary figure 1B). We also noted a reduction in the total number
111 of epithelial cells in the ND condition, which was significantly reversed in the presence of SP
112 (figure 1H).

113 ***SP increases absorption in nutrient-deficient Intestine Chips***

114 Nutritional components including fatty acids and vitamins help to maintain healthy gut
115 homeostasis and prevent intestinal inflammation, and the absorption of fatty acids, zinc, and
116 triglyceride in pregnant women is crucial for normal fetal tissue development and birth
117 outcomes.^{13,14} When RNA-seq analysis of epithelial cells obtained from Healthy Intestine Chips,
118 ND chips, and ND chips with SP treatment was carried out, we detected 594 genes (adjusted $p <$
119 0.05 and $\log_2(\text{fold change}) \geq 1.0$; 149 upregulated, 445 downregulated) that were differentially
120 regulated in the ND condition compared to healthy controls. Intestinal epithelial cells exposed to
121 ND medium exhibited lower expression of lipoproteins (APOA1, APOC3), solute carrier (SLC)
122 transporters (SLC2A5, SLC6A13, SLC28A1), and mucins (MUC2) compared to healthy chip
123 controls (figure 2A). Functional enrichment analysis demonstrated that nutritional deficiency

124 suppressed pathways related to digestion, the triglyceride metabolic process, intestinal
125 absorption, the fatty acid metabolic process, the response to zinc ion, and the vitamin metabolic
126 process, but activated epithelial cell fate commitment and regulation of the Wnt signaling pathway
127 compared with healthy chip controls (figure 2B).

128 In contrast, when we compared transcriptomic expression profiles from SP-treated ND
129 chips to untreated ND chips, we detected differential expression of 50 genes (adjusted $p < 0.05$
130 and $\log_2(\text{fold change}) \geq 1.0$; 11 upregulated, 39 downregulated). The cells from ND+SP chips
131 exhibited higher expression of various genes related to key enzymes in the small intestine
132 (AADAC, NAGS, HMCN2), intestinal mucus homeostasis (CLCA1), a transporter for water-
133 soluble vitamins (SLC52A1), a mediator for iron ion and oxygen binding (HAAO), those involved
134 in cell recognition and behaviors (CATSPERD, ZAN, HTR1D), and protein processing (SPON1)
135 during pregnancy compared to the untreated ND condition (figure 2C).¹⁵⁻¹⁸ Functional enrichment
136 analysis indicated that cells in SP-treated ND chips reactivated various metabolic processes
137 (water-soluble vitamin, alpha-amino acid, tryptophan, arginine, and lipid), and biological pathways
138 (urea cycle, intestinal smooth muscle contraction, and glutamine biosynthesis), but suppressed
139 regulation of the Wnt signaling pathway, cell morphogenesis, and neuro maturation compared
140 with ND chips (figure 2D). Gene set enrichment analysis (GSEA) also showed that genes involved
141 in fatty acid and bile acid metabolism are upregulated in healthy control and ND+SP chips
142 compared to ND chips (figure 2E). Consistent with these findings, when we further analyzed
143 cellular uptake of fatty acids using a fluorescently labeled dodecanoic acid, we found a 3.5-fold
144 reduction in fatty acid uptake in ND chips compared to healthy chip controls, and treatment with
145 SP significantly reversed this effect (figure 3A,B).

146 ***SP suppresses nutritional deficiency-associated inflammatory responses***

147 Malnutrition-associated enteric function also commonly results in enhanced intestinal
148 inflammation.¹⁹ Consistent with this clinical observation, we detected increased protein levels of

149 multiple pro-inflammatory cytokines, including interleukin-8 (IL-8), MIP-1 α , TNF- α , IFN- γ , IL-10,
150 IL-15, REG3A, and lipocalin-2 (LCN2) in ND Intestine Chips compared to healthy control chips
151 (figure 4A,B). Once again, treatment with SP suppressed this inflammatory response by reducing
152 levels of most of these cytokines while further increasing the production of LCN2 (figure 4B),
153 which has been reported to maintain intestinal microbiota homeostasis and protect against
154 intestinal inflammation.²⁰ This increase in inflammation observed in the ND chips was
155 accompanied by epithelial damage and apoptosis, as indicated by increased Caspase-3
156 immunostaining, and again this was reversed by SP treatment (figure 4C,D). Furthermore, when
157 we introduced human peripheral blood mononuclear cells (PBMCs) into the endothelium-lined
158 vascular channel of the chip, increased numbers of these immune cells became adherent to the
159 surface of the epithelium in ND chips compared with healthy chip controls. Importantly, this
160 inflammatory recruitment of immune cells was also significantly inhibited by SP treatment (figure
161 4E,F). We also performed flow cytometric analysis of the adherent immune cells, and did not
162 detect any significant changes in the distribution of T cells, B cells, or monocytes under the
163 different experimental conditions (supplementary figure 3).

164

165 **DISCUSSION**

166 The high incidence of low birth weight newborns in women with malnutrition is a critical
167 problem in low-resource nations and a major international issue because it is associated with
168 increased infant mortality and developmental delays in children. The serendipitous finding that SP
169 antimalarial therapy reduces the incidence of lower birth weight infants in pregnant women in sub-
170 Saharan Africa has raised the possibility that this antibiotic combination might have direct effects
171 on maternal physiology that are independent of its antimicrobial actions. In the present study, we
172 investigated this directly by leveraging Organ Chip technology to engineer human Intestine Chips

173 lined with young adult female patient-derived duodenal epithelial cells interfaced with endothelial
174 cells and by mimicking ND using nutrient-reduced growth medium lacking niacinamide and
175 tryptophan. We have previously demonstrated that human Intestine Chips cultured under these
176 ND conditions replicate the EED phenotype observed clinically.^{5,21} Importantly, our results show
177 that SP treatment significantly improved conditions of villus blunting, compromised barrier function,
178 mucus layer thinning, and reduced nutrient absorption, and it also prevented epithelial cell death,
179 which are all induced by ND conditions in human Intestine Chips. SP treatment also suppresses
180 the release of inflammatory cytokines and inhibits the recruitment of circulating immune cells.
181 Thus, SP does indeed have direct effects on the human adult female intestine that could in part
182 explain the improved birth weights seen in malnourished mothers who were treated with SP as
183 an antimalarial therapy.^{4,22}

184 SP appears to alleviate intestinal dysfunction induced by nutritional deficiencies in multiple
185 ways based on our in vitro studies with human Intestine Chips. First, it restores a more normal
186 villus architecture with increased intestinal surface area that is available to absorb digested food
187 molecules. Second, SP treatment of the ND intestine also improves the secretion of mucins and
188 increases the thickness of the intestinal mucus layer that normally lubricates the epithelial surface
189 and protects the epithelium from commensal microorganisms, invading pathogens, and other
190 environmental irritants.²³ Third, SP induces the expression of multiple genes that are crucial for
191 the efficient absorption of nutrients and fatty acids, which are extremely important during
192 pregnancy for both maternal and fetal health.²⁴ In particular, we found that ND conditions reduce
193 fatty acid absorption in the intestinal epithelium and that treatment with SP counters this inhibition.
194 Genes involved in fatty acid uptake, transport, and metabolism, which are important for
195 maintaining both glucose and energy homeostasis,²⁵ are also downregulated in the ND condition
196 compared with healthy controls, and again SP treatment largely reverses this effect. Interestingly,
197 we found that SP treatment stimulates the metabolism of bile acids, which are known to play

198 multiple roles in lipid metabolism and serve as signaling molecules in the small intestine by
199 modulating lipid, glucose, and energy homeostasis, in addition to supporting the absorption of
200 dietary lipids.

201 In the living intestine, there is an intricate interplay between intestinal epithelial cells and
202 the mucosal immune system,²⁶ which becomes deregulated leading to increased inflammation in
203 patients with EED or other forms of intestinal dysfunction. Similarly, we found that culturing healthy
204 Intestine Chips lined by epithelium from young adult female donors in the presence of ND medium
205 resulted in increased production of multiple pro-inflammatory cytokines, which is consistent with
206 what we observed previously in chips lined by cells from EED patients when exposed to nutritional
207 deficiency.⁵ Interestingly, after SP treatment, these elevated cytokine levels in the ND Intestine
208 Chips reduced significantly when the chips were treated with SP. The only exception was LCN2,
209 which was induced by SP. This is interesting because LCN2 is known to suppress inflammation
210 in the intestine by multiple mechanisms including protecting the barrier against oxidative stress,
211 enhancing phagocytic bacterial clearance, maintaining homeostasis with the commensal
212 microbiome, and modulating immune responses.²⁷ Consistent with these observations, we found
213 that when we introduced PBMCs into the endothelium-lined vascular channel of the Intestine
214 Chips, ND increased immune cell recruitment whereas SP treatment greatly reduced this
215 response.

216 Taken together, these results show that SP can indeed have multiple direct effects on
217 human intestinal structure and function that could explain the serendipitous observation of
218 reduced incidence of low birth weight newborns, which is seen in pregnant women after anti-
219 malaria treatment with SP. Most importantly, these findings suggest that SP should be further
220 explored as a potential treatment for this important global health issue, and that the human
221 Intestine Chip also may prove useful to address other questions relating to intestinal physiology
222 and pathophysiology that are of interest to the global health community.

223 **METHODS**

224 **Preparation of Intestine Chips and SP treatment**

225 Intestinal organoids were generated from biopsy samples from healthy regions of the
226 duodenum in patients being evaluated for potential other intestinal problems, as described,^{5,8} and
227 all methods were performed according to the approval of the Institutional Review Board of Boston
228 Children's Hospital (Protocol number IRB-P00000529). Our methods for culturing patient-derived
229 epithelial intestinal organoids, enzymatically releasing the cells, and then culturing them within
230 one channel of a two-channel microfluidic organ chip device (Emulate Inc.) separated by a porous
231 membrane from primary human microvascular endothelial cells in the second channel, have been
232 described previously.^{5,9} The upper epithelial channel was perfused with complete medium or ND
233 medium without niacinamide and tryptophan at 60 μ L/h to mimic the EED state, while the lower
234 channel was perfused with expansion culture medium. Sulfadoxine (S; 200 mg, USP) and
235 pyrimethamine (P; 200 mg, USP) were prepared in 0.5 mL DMSO (ThermoFisher), and mixed
236 with differentiation medium (DM) at a ratio of 20:1 (133 μ g S + 6.7 μ g P)/mL which simulates the
237 acute duodenal exposure at the WHO recommended dose (500 mg S + 25 mg P/tablet) of the SP
238 formulation (192 μ g S + 9.6 μ g P)/chip for 1 day; equivalent to 1 SP tablet in 250 mL gastric
239 volume considering the gastric volume of a healthy adult (250-300 mL); these drugs were then
240 perfused through the epithelial channel for 3 days.

241 **Morphological analysis**

242 For immunofluorescence microscopic imaging, tissues within either whole or Vibratome
243 (Leica VT1000S) sectioned chips were fixed with 4% paraformaldehyde (PFA), permeabilized,
244 and blocked with 0.1% Triton X-100 solution and 10% donkey serum in PBS. Barrier integrity was
245 assessed using antibodies directed against ZO-1 (Invitrogen, 33-9100), VE-Cadherin
246 (ThermoFisher, ab33168), and species-specific secondary antibodies (Invitrogen, A31570 and

247 Invitrogen, A31571); nuclei were stained with Hoechst 33342 (Invitrogen, H3570). Pseudo
248 hematoxylin and eosin (H&E) staining was carried out on 40-60 μm chip sections, as described.
249 ¹⁰ Imaging was carried out using a laser scanning confocal microscope (Leica SP5 X MP DMI-
250 6000), and IMARIS (Ver. 9.9.1, Oxford Instruments) and ImageJ software were used for
251 processing and analysis of 3D high-resolution horizontal or vertical cross-sectional images.

252 **Intestinal barrier permeability**

253 We assessed the paracellular permeability of the intestinal barrier within Intestine Chips
254 as previously described using the small fluorescent biomarker, Cascade Blue (596 Da;
255 ThermoFisher, C687).¹¹ Briefly, the apical-to-basolateral flux of the paracellular marker was
256 calculated using the following formula: $P_{app} = (V_r \times C_r) / (t \times A \times C_d \text{ out})$, where V_r is the volume of
257 the receiving channel outflow, C_r is the concentration of tracer in the receiving channel, t is time
258 (sec), A is the total area of diffusion (cm^2), and $C_d \text{ out}$ is the concentration of tracer in the dosing
259 channel outflow (mg/mL).

260 **Mucus accumulation**

261 Intestinal mucus was visualized on-chip using wheat germ agglutinin (WGA)-Alexa 488
262 (ThermoFisher).⁵ Briefly, 25 $\mu\text{g}/\text{mL}$ of WGA in Hanks' Balanced Salt Solution (HBSS, Gibco) was
263 flowed at 200 $\mu\text{L}/\text{h}$ through the apical channel for 30 min and then washed with continuous flow
264 of HBSS at the same flow rate for 30 min. The entire channel was visualized with a fluorescence
265 microscope (Excitation/Emission=488/523nm, Zeiss Axio Observer Z1). For MUC5B visualization,
266 immunofluorescence microscopic imaging was carried out on 150-200 μm chip sections using
267 antibodies against MUC5B (Invitrogen, 37-7400) and a secondary antibody (ThermoFisher,
268 A31571). The MFI intensity of MUC5B staining was quantified using ImageJ.

269 **Fatty acid uptake**

270 Fatty acid (FA) absorption was measured as described.⁵ Briefly, the media in the apical

271 and basal channels of the Intestine Chips were switched to HBSS for 1 h. A fluorescently labeled
272 dodecanoic acid containing a quencher (10 μ L quencher + 5 μ L FA + 485 μ L assay buffer + 500
273 μ L HBSS) was then added to the apical channel according to the manufacturer's instructions
274 (BioVision, K408). Fluorescence microscopic imaging of the epithelial channel was then carried
275 out (Excitation/Emission=488/523nm, Zeiss Axio Observer Z1 and Echo Revolve microscope)
276 and FA uptake was calculated by determining fluorescence intensity levels using ImageJ.

277 **Transcriptomic analysis**

278 RNA sequencing analysis of epithelial cells removed from the chips by exposure to
279 Accumax™ (STEMCELL Technologies) was performed by AZENTA Life Sciences (NJ, USA).
280 Briefly, RNA was isolated using RNeasy Plus Micro Kit (Qiagen) and the samples were evaluated
281 for RNA quality. Libraries were sequenced using the Illumina HiSeq4000 platform, and the
282 resulting 150bp long pair-ended reads were trimmed using Trimmomatic (v.0.36) mapped to
283 GRCh38 reference genome using STAR (v.2.5.2); gene hit counts to ENSEMBL Release 105
284 transcriptome annotation were generated using featureCounts of Subread package (v.1.5.2) for
285 downstream analysis. Differential gene expression analysis was performed using DESeq2
286 (v.1.26.0) with the Benjamini and Hochberg method for adjusting p -values for multiple hypothesis
287 testing. Genes with adjusted p -values < 0.05 and absolute $\log_2(\text{fold change}) \geq 1$ were considered
288 differentially expressed. Relevant biological pathways were identified in the MSigDB Hallmark
289 2020 database using gene set enrichment analysis (GSEA).¹²

290 **Inflammatory cytokine production**

291 Changes in cytokine levels were measured in apical channel effluents from our chips.¹¹
292 Ten inflammatory cytokines were selected and a Luminex assay was conducted according to the
293 manufacturer's protocol (Invitrogen). Analyte concentrations were measured using a Luminex
294 FLEXMAP 3D instrument with xPONENT® software. For apoptosis analysis, cleaver Caspase-3

295 (Cell Signaling Technology, 9661S) was stained with a secondary antibody (ThermoFisher,
296 A31572) and imaged with a laser scanning confocal microscope (Leica); the fluorescence
297 intensity was measured using ImageJ.

298 **Immune cell recruitment**

299 We quantified the effects of SP on the recruitment of immune cells through the
300 endothelium and to the epithelium by perfusing PBMCs through the lower endothelium-lined
301 channel, as previously described.¹¹ Briefly, de-identified human patient-derived apheresis collars
302 were obtained from the Crimson Biomaterials Collection Core Facility under approval obtained
303 from the Institutional Review Board at Harvard University (#22470). Cells were stained with
304 CellTracker Green™ CMFDA (1:1,000 v/v in PBS, ThermoFisher, #C7025) for 10 min at 37°C in
305 a water bath and stained PBMCs were then seeded into the basal channel (endothelium) of the
306 Intestine Chips at 5×10^7 cells/mL in medium. PBMCs were allowed to adhere to the endothelium
307 by inverting the chips for 3 h under a static condition, were gently washed with complete medium
308 to remove non-adherent or suspended cells, and were then maintained at continuous flow (60
309 μ L/h). The number of PBMCs that adhered and migrated from the basal vascular channel to the
310 apical epithelium-lined channel was quantified by immunofluorescence microscopic imaging. The
311 composition of these PBMCs recruited to the epithelium was determined using Flow Cytometry
312 (CytoFlex LX); cell digests were stained with Viakrome 808 Live/Dead stain (Beckman Coulter,
313 C36628), CD19 BV421 (BioLegend, 302234), CD3 APC-H7(BD Biosciences, 560176), and CD14
314 BV395 (BD Biosciences, 563561), and then fixed with 200 μ L of Cytifix (BD Biosciences, 554655).
315 To calculate the absolute number of cells per sample, 5025 counting beads were added to each
316 sample. Results were analyzed using FlowJo V10 software (FlowJo, LLC).

317 **Statistical analysis**

318 Between 3 and 6 Intestine Chips were used in each study and a Two-tailed Student's t-

319 test was performed to determine statistical significance, as indicated in the figure legends. $P <$
320 0.05 were considered significant; error bars indicate mean \pm standard deviation (s.d.).

321

322

323

324

325

326

327

328

329

330

331 **REFERENCES**

- 332 1. Gernand AD, Schulze KJ, Stewart CP, West KP, Jr., Christian P. Micronutrient deficiencies in
333 pregnancy worldwide: health effects and prevention. *Nat Rev Endocrinol* 2016; **12**(5): 274-89.
- 334 2. Abu-Saad K, Fraser D. Maternal nutrition and birth outcomes. *Epidemiol Rev* 2010; **32**: 5-25.
- 335 3. Deloron P, Bertin G, Briand V, Massougbdji A, Cot M. Sulfadoxine/pyrimethamine intermittent
336 preventive treatment for malaria during pregnancy. *Emerg Infect Dis* 2010; **16**(11): 1666-70.
- 337 4. Kayentao K, Garner P, van Eijk AM, et al. Intermittent preventive therapy for malaria during
338 pregnancy using 2 vs 3 or more doses of sulfadoxine-pyrimethamine and risk of low birth weight in
339 Africa: systematic review and meta-analysis. *JAMA* 2013; **309**(6): 594-604.
- 340 5. Bein A, Fadel CW, Swenor B, et al. Nutritional deficiency in an intestine-on-a-chip recapitulates
341 injury hallmarks associated with environmental enteric dysfunction. *Nat Biomed Eng* 2022; **6**(11): 1236-
342 47.
- 343 6. Soderholm AT, Pedicord VA. Intestinal epithelial cells: at the interface of the microbiota and
344 mucosal immunity. *Immunology* 2019; **158**(4): 267-80.
- 345 7. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease.
346 *Cell Res* 2020; **30**(6): 492-506.
- 347 8. Sato T, Stange DE, Ferrante M, et al. Long-term expansion of epithelial organoids from human
348 colon, adenoma, adenocarcinoma, and Barrett's epithelium. *Gastroenterology* 2011; **141**(5): 1762-72.
- 349 9. Kasendra M, Tovaglieri A, Sontheimer-Phelps A, et al. Development of a primary human Small
350 Intestine-on-a-Chip using biopsy-derived organoids. *Sci Rep* 2018; **8**(1): 2871.
- 351 10. Elfer KN, Sholl AB, Wang M, et al. DRAQ5 and Eosin ('D&E') as an Analog to Hematoxylin and
352 Eosin for Rapid Fluorescence Histology of Fresh Tissues. *PLoS One* 2016; **11**(10): e0165530.
- 353 11. Bein A, Kim S, Goyal G, et al. Enteric Coronavirus Infection and Treatment Modeled With an
354 Immunocompetent Human Intestine-On-A-Chip. *Front Pharmacol* 2021; **12**: 718484.
- 355 12. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based
356 approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 2005; **102**(43):
357 15545-50.
- 358 13. Morrison JL, Regnault TR. Nutrition in Pregnancy: Optimising Maternal Diet and Fetal
359 Adaptations to Altered Nutrient Supply. *Nutrients* 2016; **8**(6).
- 360 14. Vrijkotte TG, Algera SJ, Brouwer IA, van Eijnsden M, Twickler MB. Maternal triglyceride levels
361 during early pregnancy are associated with birth weight and postnatal growth. *J Pediatr* 2011; **159**(5):
362 736-42 e1.
- 363 15. Geng M, Li T, Kong X, et al. Reduced expression of intestinal N-acetylglutamate synthase in
364 suckling piglets: a novel molecular mechanism for arginine as a nutritionally essential amino acid for
365 neonates. *Amino Acids* 2011; **40**(5): 1513-22.
- 366 16. Mosegaard S, Bruun GH, Flyvbjerg KF, et al. An intronic variation in SLC52A1 causes exon
367 skipping and transient riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. *Mol Genet*

- 368 *Metab* 2017; **122**(4): 182-8.
- 369 17. Amir Shaghaghi M, Bernstein CN, Serrano Leon A, El-Gabalawy H, Eck P. Polymorphisms in the
370 sodium-dependent ascorbate transporter gene SLC23A1 are associated with susceptibility to Crohn
371 disease. *Am J Clin Nutr* 2014; **99**(2): 378-83.
- 372 18. Hong W, Guo F, Yang M, et al. Hydroxysteroid sulfotransferase 2B1 affects gastric epithelial
373 function and carcinogenesis induced by a carcinogenic agent. *Lipids Health Dis* 2019; **18**(1): 203.
- 374 19. Guerrant RL, Oria RB, Moore SR, Oria MO, Lima AA. Malnutrition as an enteric infectious disease
375 with long-term effects on child development. *Nutr Rev* 2008; **66**(9): 487-505.
- 376 20. Moschen AR, Gerner RR, Wang J, et al. Lipocalin 2 Protects from Inflammation and
377 Tumorigenesis Associated with Gut Microbiota Alterations. *Cell Host Microbe* 2016; **19**(4): 455-69.
- 378 21. Nyaradi A, Li J, Hickling S, Foster J, Oddy WH. The role of nutrition in children's neurocognitive
379 development, from pregnancy through childhood. *Front Hum Neurosci* 2013; **7**: 97.
- 380 22. ter Kuile FO, van Eijk AM, Filler SJ. Effect of sulfadoxine-pyrimethamine resistance on the efficacy
381 of intermittent preventive therapy for malaria control during pregnancy: a systematic review. *JAMA* 2007;
382 **297**(23): 2603-16.
- 383 23. Grondin JA, Kwon YH, Far PM, Haq S, Khan WI. Mucins in Intestinal Mucosal Defense and
384 Inflammation: Learning From Clinical and Experimental Studies. *Front Immunol* 2020; **11**: 2054.
- 385 24. Duttaroy AK, Basak S. Maternal dietary fatty acids and their roles in human placental
386 development. *Prostaglandins Leukot Essent Fatty Acids* 2020; **155**: 102080.
- 387 25. Rui L. Energy metabolism in the liver. *Compr Physiol* 2014; **4**(1): 177-97.
- 388 26. Takiishi T, Fenero CIM, Camara NOS. Intestinal barrier and gut microbiota: Shaping our immune
389 responses throughout life. *Tissue Barriers* 2017; **5**(4): e1373208.
- 390 27. Flo TH, Smith KD, Sato S, et al. Lipocalin 2 mediates an innate immune response to bacterial
391 infection by sequestering iron. *Nature* 2004; **432**(7019): 917-21.

392

393

394

395

396

397

398

399 **Acknowledgments**

400 This study was funded by the Bill and Melinda Gates Foundation and the Wyss Institute for
401 Biologically Inspired Engineering at Harvard University. We would like to thank Thomas C.
402 Ferrante and Alican Ozkan for their help in processing the images. We also thank Gwenn E. Merry
403 for editing this manuscript.

404 **Contributors**

405 S.K. led this study, and S.K., G.G., and D.E.I. designed the overall research. S.K., A.N., and P.P.
406 performed experiments. S.K., V.H., A.J., G.G., and D.E.I. analyzed and interpreted all the data.
407 D.T.B. established human intestinal organoids. S.K. and D.E.I. wrote the article with input from
408 other authors.


409 **Data sharing**

410 The datasets and analysis will be available upon request. All requests should be addressed to the
411 corresponding author (don.ingber@wyss.harvard.edu).

412 **Declaration of interests**

413 D.E.I. holds equity in Emulate, Inc., chairs its scientific advisory board, and is a member of its
414 board of directors. The other authors declare no competing interests.

415 **FIGURE LEGENDS**




416

417 **Figure 1: Effect of nutritional deficiency and SP treatment on adult female Intestine Chip**

418 (A) A schematic cross-sectional view of the duodenal organoid-derived Intestine Chip showing the
 419 apical (epithelium) and basal (endothelium) microchannels. The sulfadoxine-pyrimethamine (SP)
 420 drug combination was applied to the apical channel and the human peripheral blood mononuclear
 421 cells (PBMCs) were applied to the basal channel. (B) Immunofluorescence imaging of cross-

422 sectioned Intestine Chips showing villus-like structures, green: phalloidin, yellow: ZO-1, blue:
423 Hoechst 33342. Scale bar = 50 μm . (C) Differences in villus-like structure height between normal
424 (Con), nutritionally deficient (ND), and SP-treated ND (ND+SP) Intestine Chips. $**p < 0.01$, $****p$
425 < 0.0001 by Two-tailed Student's t-test. (D) Apparent permeability (P_{app}) after SP treatment. $*p <$
426 0.05 , $***p < 0.001$ by Two-tailed Student's t-test. (E) Immunofluorescence imaging of Intestine
427 Chips stained with wheat germ agglutinin (WGA) with Alexa-488 conjugated lectin showing mucus
428 production. Scale bar = 200 μm . (F) Differences in fluorescence intensity of WGA. $**p < 0.01$, $***p$
429 < 0.001 , $****p < 0.0001$, by Two-tailed Student's t-test. (G) Differences in fluorescence intensity
430 of MUC5B. $***p < 0.001$ by Two-tailed Student's t-test. (H) Comparison of cell number between
431 Con, ND, and ND+SP Intestine Chips. $*p < 0.05$, $***p < 0.001$ by Two-tailed Student's t-test.



432

433 **Figure 2: Reversal of impaired absorption in nutrient-deficient Intestine Chips by SP**

434 **treatment** (A) Volcano plot of DEGs from nutritionally deficient (ND) chips compared to control

435 (Con) chips. (B) Dot plot showing the biological processes activated or suppressed by ND vs. Con


436 conditions from (A). (C) Volcano plot of DEGs found in epithelial cells from SP-treated ND chips

437 (ND+SP) compared to those from ND chips. (D) Dot plot showing the biological processes

438 activated or suppressed by ND+SP vs. ND condition from (C). (E) Gene Set Enrichment Analysis
439 (GSEA) plots showing the significant enrichment of gene sets in epithelial cells from Con vs. ND
440 and from ND+SP vs. ND conditions, respectively. MSigDB Hallmark 2020 was used for GSEA
441 plot.


442

443



444

445 **Figure 3: Impaired fatty acid absorption** (A) Fatty acid (FA) absorption assay in the Intestine
446 Chips by fluorescently-labeled (Alexa 488) dodecanoic fatty acid uptake at the 60 min time point.
447 Scale bar = 50 μ m. (B) Differences in fluorescence intensity of up-taken FA. ** $p < 0.01$, *** $p <$
448 0.001 , **** $p < 0.0001$ by Two-tailed Student's t-test.




449

450 **Figure 4: Effect of SP on inflammatory responses associated with nutritional deficiency (A)**
 451 Heatmap showing differential expression of 10 cytokines secreted into the apical (epithelium)
 452 channel of Intestine Chips at day 3 after SP treatment, measured by Luminex assay. The color-
 453 coded scale represents the log₂ fold change in expression. (B) Production of four key cytokines
 454 on day 1, day 2, and day 3 after SP treatment. White (Con), gray (ND), and dark gray (ND+SP).
 455 **p* < 0.05, ***p* < 0.01, ****p* < 0.001 by Two-tailed Student's t-test. (C) Immunofluorescence imaging


456 of the epithelial channel of Intestine Chips stained for Caspase-3 (white) and Hoechst 33342
457 (blue). Scale bar = 100 μm . (D) Differences in fluorescence intensity of Caspase-3 from Intestine
458 Chip images (C). $*p < 0.05$, by Two-tailed Student's t-test. (E) Recruitment of PBMCs in the
459 Intestine Chip. PBMCs were stained with CellTracker GreenTM CMFDA. Scale bar = 50 μm . (F)
460 Quantification of recruited PBMCs in the top channel of chips from Intestine Chip images (E). $*p$
461 < 0.05 , $***p < 0.001$ by Two-tailed Student's t-test.

462 **Supplementary Data**




463

464 **Supplementary Figure 1: Morphological characteristics of Intestine Chips** (A) Pseudo-H&E stained
465 images of the intestinal epithelium on Intestine Chips. Red arrows indicate regions of potentially damaged
466 epithelium and pseudostratified cytoskeleton. Scale bar = 50 μm . (B) Immunofluorescence imaging of
467 cross-sectioned Intestine Chips showing the presence of mucin, red: MUC5B, blue: Hoechst 33342. Scale
468 bar = 50 μm . The fluorescence intensity of MUC5B is shown in figure 1G. (C) Immunofluorescence imaging
469 of the basal channel (endothelium) of Intestine Chips stained with VE-Cadherin (white) and Hoechst (gray).
470 Scale bar = 50 μm .



471

472 **Supplementary Figure 2: Optimal dose-finding for an Intestine Chip model** (A) Phase-contrast imaging
 473 of Intestine Chips. Intestine Chips were treated with DMSO only (control) or different doses of SP dissolved
 474 in DMSO. The epithelial channel of the Intestine Chip was perfused with the calculated acute duodenal
 475 dose ([133 μg S + 6.7 μg P]/mL) of this formulation as well as lower doses (1/50th [2.66 μg S + 0.13 μg
 476 P]/mL and 1/10th [13.3 S + 0.67 μg P]/mL) in culture medium. Scale bar = 100 μm . (B) Apparent
 477 permeability (P_{app}) after SP treatment with different doses. (C) Cytokine analysis at day 1, day 2, and day
 478 3 after SP treatment was measured by Luminex assay in the effluent from the apical (epithelium) channel
 479 of Intestine Chips. * $p < 0.05$ by Two-tailed Student's t-test.



480

481 **Supplementary Figure 3: Composition of recruited immune cells.** PBMCs were collected from Intestine
482 Chips and identified by FACS. Orange (T-cells by CD3), green (Monocytes by CD14), and blue (B-cells by
483 CD19).